1. Home
  2. INBK vs NKTX Comparison

INBK vs NKTX Comparison

Compare INBK & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Internet Bancorp

INBK

First Internet Bancorp

HOLD

Current Price

$23.92

Market Cap

179.3M

Sector

Finance

ML Signal

HOLD

Logo Nkarta Inc.

NKTX

Nkarta Inc.

HOLD

Current Price

$3.04

Market Cap

188.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INBK
NKTX
Founded
1999
2015
Country
United States
United States
Employees
355
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
179.3M
188.9M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
INBK
NKTX
Price
$23.92
$3.04
Analyst Decision
Hold
Strong Buy
Analyst Count
2
4
Target Price
$23.25
$11.33
AVG Volume (30 Days)
56.1K
749.2K
Earning Date
04-30-2026
05-11-2026
Dividend Yield
1.06%
N/A
EPS Growth
N/A
11.88
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$279.34
N/A
Revenue Next Year
$12.97
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$17.05
$1.63
52 Week High
$28.51
$3.65

Technical Indicators

Market Signals
Indicator
INBK
NKTX
Relative Strength Index (RSI) 50.19 55.80
Support Level $23.26 $1.88
Resistance Level $24.85 $3.35
Average True Range (ATR) 0.79 0.22
MACD -0.17 -0.03
Stochastic Oscillator 24.68 59.33

Price Performance

Historical Comparison
INBK
NKTX

About INBK First Internet Bancorp

First Internet Bancorp is a bank holding company. Through its subsidiaries, it provides commercial real estate (CRE) lending, including nationwide single tenant lease financing and commercial and industrial (C&I) lending, including business banking or treasury management services. The company offers its products and services through the internet and does not have any branches. With operations organized into a single segment called the Commercial Banking segment, it also provides retail banking services.

About NKTX Nkarta Inc.

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

Share on Social Networks: